Focus Partners Advisor Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Focus Partners Advisor Solutions's VRTX Position: Q2 2026 in Review
Focus Partners Advisor Solutions increased its Vertex Pharmaceuticals (VRTX) stake by 90% in Q2 2026, buying an estimated $359K and bringing the position to 1,708 shares worth $849K. The position accounts for 0.01% of the portfolio, ranked #629.
Focus Partners Advisor Solutions first reported a position in VRTX in Q1 2024 and has held it in 5 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Focus Partners Advisor Solutions held 1,708 shares of Vertex Pharmaceuticals worth $849K as of Q2 2026.
- Focus Partners Advisor Solutions bought 811 Vertex Pharmaceuticals shares in Q2 2026, an estimated $359K.
- Vertex Pharmaceuticals made up 0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #629 holding.
- Focus Partners Advisor Solutions first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
- 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.